TMCnet - World's Largest Communications and Technology Community



Research and Markets: Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022
[April 17, 2014]

Research and Markets: Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering.

Aripiprazole lauroxil is a novel lipid ester prodrug of aripiprazole that utilizes Alkermes' proprietary LinkeRx technology for once-monthly drug delivery. Once administered IM, aripiprazole lauroxil is converted to aripiprazole, a 5-HT2A antagonist/D2 and 5-HT1A partial agonist that is marketed as Abilify by Otsuka. Alkermes' aripiprazole lauroxil differs from Otsuka/Lundbeck's once-monthly formulation of Abilify, called Abilify Depot, in that it is supplied as a suspension and does not require reconstitution prior to administration.


  • Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Dtailed information on Aripiprazole Lauroxil including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Aripiprazole Lauroxil for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.2 Symptoms

4 Disease Management

4.1 Diagnosis

4.1.1 Subjective Assessments

4.1.2 Disease Subtypes

4.2 Treatment Overview

4.2.1 Treatment of Acute Agitation Associated with Schizophrenia

4.2.2 Maintenance Treatment of Schizophrenia

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitor Assessment

6 Opportunity and Unmet Need

6.1 Unmet Needs Overview

6.1.1 Public Awareness

6.1.2 Early Diagnosis and Treatment

6.1.3 Long-Acting and Advanced Drug Delivery Systems

6.1.4 Effective Management of Negative and Cognitive Symptom Domains

6.2 Gap Analysis

6.2.1 Long-Acting Drug Delivery

6.2.2 Treatment of Negative and Cognitive Symptoms

7 Pipeline Assessment

7.1 Overview

7.2 Early-Stage Pipeline Assessment

7.3 Novel Therapeutic Approaches

7.3.1 Negative Symptoms

7.3.2 Cognitive Symptoms

7.4 Long-Acting Drug Delivery

7.5 Technology Trends Analysis

7.6 Key Drugs in Clinical Development

8 Aripiprazole Lauroxil

8.1 Overview

8.2 Efficacy

8.3 Safety

8.3.1 Dosing and Formulation

8.3.2 Potential Clinical Positioning

8.3.3 Potential Commercial Positioning

8.3.4 Pricing and Reimbursement

8.4 SWOT Analysis

8.5 Forecast

9 Appendix

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy